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Lung cancer is the commonest fatal malignancy in the developed
world. Small-cell lung cancer (SCLC), which constitutes 25% of
the total, is a particularly aggressive form of lung cancer. It metas-
tasises early, and over 90% of patients have widespread metastasis
at presentation, precluding curative surgery. Once SCLC was
understood to be a systemic disease, systemic chemotherapy
became the treatment of choice. However, despite initial sensi-
tivity to radio- and chemotherapy, SCLC almost invariably
relapses, so that the 2-year survival remains less than 5% (Smyth
et al, 1986). The incidence of lung cancer deaths is expected to rise
even further in the next 20 years, with an increasing number of
cases unrelated to smoking. The epidemic proportions of lung
cancer are sharply contrasted by the general failure of conven-
tional treatment. Novel forms of treatment are urgently required.
SCLC proliferation is driven by multiple autocrine and paracrine
growth loops involving calcium-mobilizing neuropeptides,
including bradykinin, cholecystokinin, galanin, gastrin, gastrin-
releasing peptide (GRP), neurotensin and vasopressin (Moody et al,
1981; Cuttitta et al, 1985; Zachary et al, 1986; Sethi and Rozengurt,
1991). The binding of these peptides to their receptors is a critical
factor in the aggressive growth of SCLC (Woll and Rozengurt,
1990; Sethi and Rozengurt, 1991a; Sethi et al, 1992). In SCLC
cells, neuropeptides acting via Gq stimulate a rise in intracellular
Ca2+ via the activation of phospholipase C (PLC) and subsequent
generation of inositol phosphates (Woll and Rozengurt, 1989; Sethi
and Rozengurt, 1991a, 1991b). Neuropeptides also activate the
mitogen-activated protein kinase (MAPK) pathway via a protein
kinase C-dependent mechanism (Seufferlein and Rozengurt, 1996;
Seckl et al, 1997). These effects result in the activation of transcrip-
tion factors leading to an overall stimulation of cell growth and
proliferation (for review see Blumer and Johnson, 1994).
Interruption of the mitogenic second messenger signals initiated by
these neuropeptides could offer a novel and effective form of treat-
ment to prevent SCLC cell growth.
Studies on the pharmacology of a family of substance P
analogues have shown that these compounds inhibit the effects of
a broad range of neuropeptides that are structurally unrelated
to substance P and hence have been termed ‘broad-spectrum’
neuropeptide anatgonists (Woll and Rozengurt, 1990; Sethi et al,
1992). These compounds inhibit SCLC cell growth in vivo and in
vitro (Woll and Rozengurt, 1988; Sethi et al, 1992; Seckl et al,
1997). In particular, [Arg6,D-Trp7,9,NmePhe8]-substance P (6–11)
(antagonist G) is now entering phase II clinical investigation for
the treatment of SCLC. Understanding the precise mechanism of
action of antagonist G is important for the design of new anti-
cancer agents and for future clinical use but, despite the clinical
importance and the advanced stage of clinical investigation, the
precise mechanism of action of these compounds remains unclear
and controversial. Studies in Swiss 3T3 cells suggested that
substance P analogues competitively inhibit the binding of
neuropeptides to their receptors (Woll and Rozengurt, 1988; Seckl
et al, 1995, 1997), accounting for the inhibition of neuropeptide-
stimulated Ca2+ mobilization (Woll and Rozengurt, 1990), MAPK
activity and growth in both Swiss 3T3 fibroblasts and SCLC cells
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Summary [Arg6,D-Trp7,9,NmePhe8]-substance P (6–11) (antagonist G) is a novel class of anti-cancer agent that inhibits small-cell lung cancer
(SCLC) cell growth in vitro and in vivo and is entering phase II clinical investigation for the treatment of SCLC. Although antagonist G blocks
SCLC cell growth (IC50 = 24.5 ± 1.5 and 38.5 ± 1.5 mM for the H69 and H510 cell lines respectively), its exact mechanism of action is unclear.
This study shows that antagonist G stimulates apoptosis as assessed by morphology (EC50 = 5.9 ± 0.1 and 15.2 ± 2.7 mM for the H69 and H510
cell lines respectively) and stimulates c-jun-N-terminal kinase (JNK) activity in SCLC cells (EC50 = 3.2 ± 0.1 and 15.2 ± 2.7 mM). This activity is
neuropeptide-independent, but dependent on the generation of reactive oxygen species (ROS) and is inhibited by the free radical scavenger n-
acetyl cysteine. Furthermore, antagonist G itself induces inflammation (59% increase in oedema volume compared to control) and potentiates
(by 35–40%) bradykinin-induced oedema formation in vivo. In view of these results we show that, as well as acting as a ‘broad-spectrum’
neuropeptide antagonist, antagonist G stimulates basal G-protein activity in SCLC cell membranes (81 ± 12% stimulation at 10 mM), thereby
displaying a unique ability to stimulate certain signal transduction pathways by activating G-proteins. This novel activity may be instrumental for
full anti-cancer activity in SCLC cells and may also account for antagonist G activity in non-neuropeptide-dependent cancers.
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(Seckl et al, 1995, 1996, 1997). However, as well as having direct
receptor effects, short hydrophobic peptides including substance P
are able to cross or insert into cell membranes, and consequently
are able to promote G-protein-mediated activation of PLC and
other effectors (Mousli et al, 1990). In addition, some substance P
analogues can inhibit receptor/G-protein coupling by binding
directly to the G-protein (Mukai et al, 1992). Thus, the basis for
the action of substance P analogues is complex.
Withdrawal of growth factors from both normal and tumour
cells results in a specific, and highly organized, form of cell death
termed apoptosis (Kerr et al, 1972; Kyprianou et al, 1992). Factors
affecting the balance between SCLC cell proliferation and apop-
tosis will have a profound effect on tumour growth. However, the
mechanisms regulating apoptosis remain poorly understood. The
p46/p54 c-jun N-terminal kinases (JNKs) are members of the
MAPK family which activate the transcription factors c-jun and
ATF2, and are stimulated by environmental stress (e.g. heat shock,
ultraviolet, tumour necrosis factor (TNF)-a, receptor tyrosine
kinases and G-protein-linked receptors (Coso et al, 1995a; Chen et
al, 1996; Verheij et al, 1996). Activation of JNK1 has been shown
to be important for UV-induced apoptosis in SCLC cells
(Butterfield et al, 1997). Reactive oxygen species (ROS) have
been shown to be involved in events leading to apoptosis in many
cell types (Buttke and Sandstrom, 1994). ROS have been shown to
activate JNK (Laderoute and Webster, 1997), c-jun expression and
AP-1 activity (Janssen et al, 1997; Xu et al, 1997). The role of
ROS in pathways leading to programmed cell death is particularly
pertinent in cancers where the oxygen tension at the centre of
tumours may be particularly low (Bush et al, 1978).
In this study we show that, as well as inhibiting neuropeptide
responses, antagonist G has neuropeptide-independent agonist
activity in SCLC cells. The agonist activity is mediated via free
radical oxygen formation leading to JNK activation, which may be
important for antagonist G-induced apoptosis of SCLC cells in
vitro. We suggest that both of these effects are likely to be crucial
for antagonist G’s maximal anti-tumour effect in vivo.
MATERIALS AND METHODS
Materials
Swiss 3T3 fibroblasts and SCLC cell lines NCI-H69 and NCI-
H510 were purchased from the American Type Tissue Culture
Collection (Rockville, MD, USA); RPMI-1640 and DMEM were
obtained from Sigma (Poole, UK); antagonist G was a kind gift
from Peptec (Copenhagen, Denmark); male New Zealand White
rabbits were purchased from Charles River (Kent, UK); [35S]-
GTPgS (1000 Ci mmol–1), [g32P]-ATP (3000 Ci mmol–1) and [125I]-
albumin (2.5 mCi mg–1) were purchased from Amersham plc
(Amersham, UK); JNK1-FL, p42MAPK polyclonal antibodies, GST
c-jun(79), myelin basic protein and protein A/G agarose were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). All other reagents were of the purest grade available.
Cell culture
NCI-H69 and NCI-H510 SCLC cells were cultured in RPMI-1640
medium with 25 mMHEPES supplemented with 10% (v/v) fetal calf
serum, 50 U ml–1 penicillin, 50 mg ml–1 streptomycin and 5 mg ml–1
L-glutamine. Cell cultures were allowed to grow to a density of 106
per ml in a humidified atmosphere of 5% carbon dioxide 95% air at
37°C. For experimental purposes, the cells were grown in SITA
medium consisting of RPMI-1640 medium supplemented with
30 nM selenium, 5 mg ml–1 insulin, 10 mg ml–1 transferrin and 0.25%
(w/v) bovine serum albumin (BSA). Cells were quiesced in serum-
free RPMI-1640 medium containing 0.25% (w/v) BSA. In anoxic
studies, cells were incubated at 37°C in a MK3 anaerobic incubator
with 0% oxygen (Don Whitely Scientific Ltd, Yorkshire, UK).
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Figure 1 Effect of antagonist G on growth and apoptosis. (A) Growth: NCI-H69 (closed circles) and NCI-H510 (closed squares) SCLC cells were quiesced
overnight, washed and resuspended in SITA medium at a density of 5 ´ 104 cells per ml in the presence of 0–80 mM antagonist G. Total cell number was
determined using a Coulter counter (Coulter Electronics). The data is expressed as % control growth in the absence of antagonist G and each point represents
the mean ± s.e.m. of three experiments performed in duplicate. The cell number at day 9 was used for IC50 determinations. The inset shows the effect of 50 mM
antagonist G in H69 cells in the absence (G) and presence (G+NP) of bradykinin, neurotensin, vasopressin and cholecystokinin all at 1 mM. (B) Apoptosis:
SCLC cells NCI-H69 (closed circles) and H510 (closed squares) and Swiss 3T3 cells (open circles) were washed and incubated with antagonist G for 24 h at
37°C. Apoptosis was assessed morphologically as described (Tallet et al, 1996). The data are expressed as % increase in apoptosis and represents the
mean ± s.e.m. of four independent experiments performed in triplicate. The inset shows the effect of 50 mM antagonist G in H69 cells on basal apoptosis in
the absence (G) and presence (G+NP) of bradykinin, neurotensin, vasopressin and cholecystokinin all at 1 mM1028 AC MacKinnon et al
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Swiss 3T3 cells were maintained in Dulbecco’s modified Eagles
medium (DMEM) containing 10% (v/v) fetal calf serum, 50 U ml–1
penicillin, 50 mg ml–1 streptomycin and 5 mg ml–1 L-glutamine.
SCLC growth
SCLC cells, 3–5 days post-passage, were washed and resuspended
in SITA medium at a density of 5 ´ 104 cells per ml in the presence
of 0–80 mM antagonist G. At each time point cell clusters were
disaggregated by passing the cell suspension through 19- and 21-
gauge needles and the total cell number was determined using a
Coulter counter (Coulter Electronics).
Measurement of apoptosis
SCLC cells were cultured in SITA medium and quiesced overnight
in serum-free medium. SCLC cells (106 cells per ml) or quiescent
cultures of Swiss 3T3 cells in 33-mm plates were incubated in the
presence or absence of antagonist G or other test agents for 24 h.
Adherent and non-adherent cells were cytocentrifuged onto glass
slides, fixed with methanol, stained with May–Grünwald–Giemsa
stain and examined using an Olympus BH-2 microscope, at a
magnification of ´400. Apoptotic SCLC cells displayed typical
morphological features, including cell shrinkage and chromatin
condensation as previously detailed (Tallet et al, 1996). The
percentage of apoptotic cells was estimated from > 500 cells
counted from 4–5 random fields.
Rabbit model of inflammation
Oedema formation was measured using a rabbit skin model of
inflammation (Williams, 1979; Armstrong et al, 1995). Briefly, New
Zealand white rabbits (male, 2–3 kg) were anaesthetized with
sagatal (30 mg kg–1 intravenously (i.v.)). The backs were shaved and
marked out with four latin squares of 15 injection sites. [125I]-
Albumin (5 mCi Amersham) made up in Evans blue dye solution
(2.5% (v/v) in sterile saline) was injected i.v. 5 min before inflam-
matory mediators were injected intradermally (i.d.) into the rabbit
skin. After 30 min, the animal was sacrificed with an overdose of
anaesthetic, and a blood sample (10 ml) taken by cardiac puncture.
This was centrifuged (450 g, 30 min) to give three aliquots (1 ml) of
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Figure 2 Effect of antagonist G on oedema formation in the rabbit skin.
Bradykinin (0.1–1.0 nmole per site) was injected in the absence (open bars)
or presence (closed bars) of antagonist G (50 nmole per site). Oedema
formation after 30 min was measured as ml plasma exudate as described in
Methods. The results represent the mean ± s.e.m. of 4–8 experiments.
*Statistically different from control P < 0.001 ANOVA
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Figure 3 Effect of antagonist G on MAPK and JNK activity in SCLC cells. (A) Time course of JNK activation. H69 cells (1 ´ 107 cells per ml) were incubated
with 25 mM antagonist G at 37°C for the times indicated. JNK activity was assessed by immunoprecipitation of the cell lysates with a polyclonal anti-JNK1
antibody and phosphorylation of GST–c-jun as described in Materials and Methods. The data are expressed as % maximal response and represent the mean ±
s.e.m. of three experiments performed in duplicate. The basal JNK activity did not change significantly during the incubation (data not shown). A representative
autoradiograph is shown. (B) Concentration dependence of JNK activation. H69 cells were incubated with antagonist G at the concentrations indicated for
60 min at 37°C. The results are expressed as % maximal response and represent the mean ± s.e.m. of 2–4 experiments performed in duplicate. A
representative autoradiograph is shown. Inset MAPK activity. H69 cells were incubated with 50 mM antagonist G (G) for 20 min or 10% (v/v) fetal calf serum
(FCS) for 10 min at 37°C. p42MAPK was immunoprecipitated from cell lysates and activity was measured as described in Materials and Methods. The data are
expressed as % control and represent the mean ± s.e.m. of three experiments performed in duplicateplasma. Injection sites (16-mm) were punched out, counted in a g-
counter, and oedema expressed as ml equivalents of plasma exudate.
Assay of MAPK and JNK activity
SCLC cells were cultured in SITA medium (5 ´ 106 per ml),
washed twice in phosphate-buttered saline (PBS) (pH 7.4), and
incubated for various times with test agents as indicated in the
Figure legends. MAPK activity was determined as described
previously (Seckl et al, 1996; Seufferlein and Rozengurt, 1996), by
immunoprecipitation with a polyclonal p42MAPK antibody and
myelin basic protein as substrate. Assessment of immunocom-
plexed JNK activity was carried out essentially as described (Coso
et al, 1995a) with minor modifications. Briefly, JNK1 was
immunoprecipitated from cell lysates using 3 mg of a specific
polyclonal antibody to JNK1 (Santa Cruz C-15 FL). Following
precipitation with protein A/G agarose, the beads were washed
twice, suspended in 20-ml kinase buffer (20 mM HEPES, pH 7.5,
7.5 mM magnesium chloride, 0.5 mM EGTA, 12.5 mM b-glycero-
phosphate, 0.5 mM sodium fluoride, 0.5 mM sodium orthovanadate
and 2 mM dithiothreitol) and incubated at 30°C for 20 min with
20 mM ATP, 1 mCi [g32P]-ATP (3000 Ci mmol–1) and 1 mg GST-c-
jun(79) substrate. Phosphorylated c-jun was identified from
autoradiographs of Coomasie blue stained sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) gels,
and quantified by optical densitometry.
Membrane preparation
SCLC cells cultured in SITA medium, were washed twice in ice-
cold PBS. The cells were lysed in ice-cold lysis buffer (10 mM
Tris–HCl pH 7.4, 5 mM EDTA, 5 mM EGTA, 1 mM phenylmethyl
sulphoxide) and briefly homogenized using a Polytron tissue
homogenizer (2 ´ 5 s setting 3). After centrifugation at 500 g for 4
min the supernatant was centrifuged at 49 000 g for 15 min at 4°C
and the pellet washed twice by repeated homogenization and
centrifugation in lysis buffer. The final pellet was suspended in 20
mM HEPES (pH 7.4), adjusted to 1 mg ml–1 protein, and stored at
–80°C. Protein was determined using Pierce BCA protein assay
reagent (Pierce, UK).
[35S]-GTPgS binding
[35S]-Guanosine 5¢-O-(g-thio)triphosphate ([35S]-GTPgS) binding
was carried out essentially as previously described (Weiland and
Jakobs, 1994). Briefly, SCLC cell membranes (~10 mg protein) were
incubated in a final volume of 100 ml binding buffer (20 mM HEPES,
pH 7.4, 100 mM sodium chloride, 3 mM magnesium chloride, 10 mM
guanosine 5¢-diphosphate (GDP), 0.2 mM ascorbate) with 0.2 nM
[35S]-GTPgS for 60 min at 4°C in the presence or absence of test
compounds. Bound radioactivity was determined by filtration onto
GF-B glass fibre filters using a Brandel Cell Harvester and counted
by scintillation spectrometry. Non-specific binding was determined
in the presence of 100 mM unlabelled GTPgS.
Statistical analysis
Data are presented as the mean ± s.e.m. of at least three separate
determinations. Statistical significance from corresponding time
control was estimated by a two-way ANOVA with significance
being taken at P < 0.05.
RESULTS
Antagonist G-induced stimulation of apoptosis and
inhibition of growth in SCLC cells is not reversed by
neuropeptides
Antagonist G profoundly inhibited the growth of SCLC cell lines
H69 and H510 in a concentration-dependent manner with IC50
values of 24.5 ± 1.5 and 38.5 ± 1.5 mM respectively (Figure 1A).
This could not be reversed by the addition of supramaximal
(1 mM) concentrations of a mixture of mitogenic neuropeptides
bradykinin, neurotensin, vasopressin and cholecystokinin (Figure
1A, inset). In addition, antagonist G caused a marked stimulation
of apoptosis as judged morphologically. The addition of antagonist
G (25 mM for 24 h) to SCLC cells cultured in SITA medium (1 ´
105 cells per ml) or Swiss 3T3 cells in 33-mm dishes caused a
marked stimulation of apoptosis (Figure 1B). In the SCLC cell line
H69, antagonist G increased basal apoptosis from 10.5 ± 4.2% to
37.1 ± 5.4% (n = 4) with an EC50 of 5.9 ± 0.1 mM (n = 4; Figure
1B). Antagonist G also induced apoptosis in the SCLC cell line
H510 with an EC50 value of 15.2 ± 2.7 mM, and in Swiss 3T3 cells
with an EC50 of 11.2 ± 3.2 mM (Figure 1B). The induction of apop-
tosis in SCLC cells by antagonist G was confirmed using acridine
orange and propidium iodide staining (not shown). As with the
effects on growth, antagonist G-induced apoptosis in H69 cells
could not be reversed by co-incubation with high concentrations
(1 mM) of a mixture of mitogenic neuropeptides (bradykinin,
neurotensin, vasopressin and cholecystokinin, Figure 1B, inset).
Antagonist G induces oedema formation in the rabbit
skin
Although antagonist G has been proposed to inhibit SCLC cell
growth by inhibiting neuropeptide growth factor responses, it has
never been shown to act as a neuropeptide antagonist in vivo. To
examine the effects of antagonist G in vivo, a rabbit skin model of
inflammation was used. In this model, bradykinin induces inflam-
mation by acting directly on endothelial cells to cause an increase
in microvascular permeability (Armstrong et al, 1995). However,
rather than inhibiting bradykinin, antagonist G (50 nmol per site)
significantly potentiated (ANOVA, P < 0.001, n = 4) oedema
formation induced by bradykinin (Figure 2), giving a 40% potenti-
ation at 0.1 nmole per site bradykinin. Furthermore, antagonist G
itself induced oedema formation in the rabbit skin when compared
to the vehicle control (27 ± 1 and 17 ± 1 ml of plasma respectively,
n = 8, P < 0.001, Figure 2). Similar results were observed if antag-
onist G was co-injected or injected 5 min prior to the addition of
bradykinin. However, unlike plasma exudation induced by
bradykinin (Armstrong et al, 1995), oedema induced by this dose
of antagonist G was not potentiated by the vasodilator action of
prostaglandin E2 (PGE2) ((1 mg per site) 26 ± 1 and 27 ± 2 ml
plasma in the absence and presence of of PGE2, n = 4). Thus antag-
onist G does not act as a competitive broad-spectrum neuropeptide
antagonist in this in vivo system.
Antagonist G stimulates JNK activity
JNK has been shown to be an important enzyme in the transduc-
tion of apoptotic and inflammatory signals in many cell types
(Coso et al, 1995a; Chen et al, 1996; Verheij et al, 1996). The
effect of antagonist G on JNK activation was therefore examined.
Antagonist G (25 mM) in the absence of neuropeptide, caused a
Antagonist G activates JNK via a ROS-dependent mechanism 1029
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marked and sustained activation of JNK activity in H69 cells. This
effect was maximal at 2 h, and sustained for at least 6 h (Figure
3A). The activation of JNK by antagonist G was concentration-
dependent (Figure 3B), with an EC50 value of 3.2 ± 0.1 mM (n = 3).
Antagonist G also activated JNK in the H510 SCLC cell line in a
similar manner (EC50 = 15.2 ± 2.7 mM, data not shown). Activation
of JNK by antagonist G did not occur as a result of non-specific
MAPK activation, as under the same conditions that antagonist G
stimulated a sustained activation of JNK, it caused only a modest
increase in MAPK activity in H69 cells, which was not evident at
concentrations lower than 25 mM (Figure 3B, inset). Therefore,
antagonist G caused a selective stimulation of JNK over MAPK
activity which may be instrumental in its ability to induce apop-
tosis in SCLC cells and cause inflammation.
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Figure 4 Antagonist G-induced apoptosis and JNK stimulation is inhibited by anoxia and n-AC. (A) Apoptosis: H69 cells cultured in SITA medium were
quiesced overnight in serum-free medium, washed and incubated (1 ´ 106 cells per ml) in the absence (open bars) or presence of 25 mM antagonist G (closed
bars) or 200 mM hydrogen peroxide (hatched bars) with or without 10 mM n-AC for 24 h at 37°C. Apoptosis was assessed morphologically as described in
Materials and Methods. The data represent the mean ± s.e.m. of 3–4 separate experiments performed in duplicate. (B) Quiescent H69 cells (1 ´ 106 cells per
ml) were incubated under normoxic (19% O2) or anoxic (MK3 anaerobic incubator, 0% O2) conditions at 37°C for 24 h in the presence (closed bars) or absence
(open bars) of 25 mM antagonist G. The data represents the mean ± s.e.m. of 3–4 separate experiments performed in duplicate. (C) JNK activity: Quiescent
cultures of H69 cells were incubated (1 ´ 107 cells per ml) in the presence (closed bars) or absence (open bars) of 25 mM antagonist G with or without 10 mM n-
AC for 1 h at 37°C. JNK activity was assessed by immunoprecipitation of the cell lysates with a polyclonal anti-JNK1 antibody and phosphorylation of GST-c-jun
as described in Materials and Methods. The data represent the mean and standard deviation of two experiments performed in duplicate. A representative
autoradiogram of JNK activity is shown. *Statistically different from corresponding control P < 0.05; **statistically different from antagonist G control P < 0.05
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Role of ROS in apoptosis and JNK activation induced
by antagonist G
The generation of free ROS is implicated in the activation of JNK
and apoptosis in certain cell systems. Understanding the role of
oxygen radicals is important in any new anti-cancer therapeutic
agent as the centre of many tumours are often profoundly hypoxic.
The role of oxidant stress on basal and antagonist G-induced
SCLC cell apoptosis was therefore examined.
Addition of the oxygen donor, hydrogen peroxide (200 mM for
24 h) caused a marked stimulation in the rate of SCLC cell apop-
tosis which was comparable to the extent of apoptosis induced by
antagonist G and was inhibited by co-incubation with the oxygen
radical scavenger n-acetylcysteine (n-AC, Figure 4A). Thus, free
radical oxygen can induce apoptosis in SCLC cells and this can be
blocked by n-AC. Incubation of SCLC cells under anoxic condi-
tions markedly attenuated the apoptotic effect of 25 mM antagonist
G (41.1 ± 2.4% to 24.7 ± 1.5%; n = 4) with only a modest rise in
the background rate of apoptosis (10.2 ± 1.4% to 18.1 ± 2.4%; n =
4) (Figure 4B). This suggests that antagonist G requires the gener-
ation of free ROS to induce apoptosis. This was confirmed using
the free radical scavenger n-AC (Figure 4A). Furthermore, n-AC
(10 mM) also markedly inhibited the antagonist G-induced activa-
tion of JNK (Figure 4C). Antagonist G did not act as an oxygen
donor itself as it had no effect on cytochrome c activity, but gener-
ated oxygen radicals within the cell as measured by an increase in
dihydrorhodamine fluorescence (results not shown).
Antagonist G stimulates G-protein activity
Our results suggest that antagonist G has direct agonist activity in
SCLC cells. We therefore postulated that antagonist G may stimu-
late G-protein activity. G-protein activity was measured in SCLC
H69 cell membranes which had been well washed to ensure
removal of endogenous neuropeptide. [35S]-GTPgS binding was
conducted in the presence of 10 mM GDP and 100 mM NaCl to
maintain G-protein in a GDP-bound form which is required for
optimal agonist activation (Weiland and Jakobs, 1994). The effect
of antagonist G was compared with the anti-cancer drug suramin,
which has been shown to block the activation of specific G-protein
a-subunits (Freissmuth et al, 1996). Suramin produced a concen-
tration-dependent inhibition of basal [35S]-GTPgS binding to H69
SCLC cell membranes (IC50 6.8 ± 1.2 mM,  n = 3; Figure 5A).
However, antagonist G, over the concentration range that inhibits
the growth of SCLC cells in vitro and in vivo produced a dose-
dependent increase in [35S]-GTPgS binding, giving a 4.1-fold stim-
ulation at 100 mM (Figure 5B). Antagonist G has been shown to be
most potent at V1A-vasopressin receptors (Seckl et al, 1995), it was
postulated therefore that the ability of antagonist G to stimulate
[35S]-GTPgS binding to SCLC cells may be via partial agonism at
V1A receptors. However, addition of a maximal concentration of
the selective V1A-receptor antagonist d(CH2)-5-TyrMe-argVP had
no effect on [35S]-GTPgS binding alone, and did not inhibit the
antagonist G-induced G-protein activation (Figure 5B), suggesting
that the agonist effect of antagonist G on G-protein activation is
not mediated via the V1A-receptor.
DISCUSSION
Antagonist G is a novel and exciting therapeutic agent for SCLC.
Antagonist G inhibits SCLC growth in vitro and in vivo and is
currently about to enter phase II clinical investigation for the treat-
ment of SCLC. However, despite this advanced stage of clinical
investigation the exact mechanism of action is controversial. It has
been proposed that unrestrained proliferation of SCLC is driven by
multiple autocrine and paracrine loops involving Ca2+-mobilizing
neuropeptides (Cuttitta et al, 1985; Sethi and Rozengurt, 1991;
Sethi, 1992). Neuropeptides have been shown to activate MAPK in
SCLC cells (Seufferlein and Rozengurt, 1996; Seckl et al, 1997),
and since antagonist G analogues inhibit neuropeptide-stimulated
MAPK activity (Mitchell et al, 1995; Seckl et al, 1997), this has
been suggested as a key mechanism for its anti-proliferative
activity. However, we have shown that as well as inhibiting growth,
antagonist G also induces apoptosis, and that both of these effects
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Figure 5 Antagonist G modulates [35S]-GTPgS binding to SCLC cell membranes. (A) H69 SCLC cell membranes (10 mg protein) were incubated with suramin
(0.01–100 mM) and 0.2 nM [35S]-GTPgS in the presence of 10 mM GDP and 100 mM sodium chloride for 60 min at 4°C. Bound [35S]-GTPgS was recovered as
described in Materials and Methods. The data are expressed as fmoles [35S]-GTPgS specifically bound/mg membrane protein and represent the mean ± s.e.m.
of four separate experiments performed in duplicate. (B) H69 SCLC cell membranes were incubated with antagonist G (0.01–300 mM) and 0.2 nM [35S]-GTPgS
in the presence (open circles) or absence (closed circles) of 1 mM d(CH2)-5-TyrMe-arginine vasopressin. The data represent the mean ± s.e.m. of four separate
experiments performed in duplicateare irreversible with neuropeptides. The H69 cell line has been
shown to respond to only six out of 32 neuropeptides tested (Woll
and Rozengurt, 1989), and was shown to be most responsive to
bradykinin and neurotensin. In our study we used supramaximal
concentrations of four of the six active neuropeptides, including
bradykinin and neurotensin, which should be able to reverse the
effects of a submaximal concentration of antagonist G if it were
acting as a competitive neuropeptide antagonist at these receptors.
Previous studies have also shown that the effects of antagonist G on
growth of H69 cells could not be reversed by GRP and galanin
(Woll and Rozengurt, 1990) the other two neuropeptides shown to
be mitogenic in these cells (Woll and Rozengurt, 1989). The
inability of these mitogens to reverse the effects of antagonist G
suggests a neuropeptide-independent mechanism of action. We
cannot rule out the possibility that there may be another, as yet
unidentified, neuropeptide receptor that is blocked by antagonist G,
but we believe that to be unlikely in the light of the known reper-
toire of receptors in SCLC cells. So, despite the well-documented
antagonistic effects of antagonist G on neuropeptide-mediated
signal transduction in vitro, these may not be the only mechanisms
responsible for its full anti-tumour activity.
It has been hypothesized that cells are intrinsically programmed
to undergo apoptosis unless they are continuously stimulated by
survival factors released from neighbouring cells (Raff et al,
1992). This is of the utmost importance in the survival and and
metastasis of cancer cells, as these cells are able to establish them-
selves at metastatic sites in distinct locations despite the dysregu-
lation of survival factors. Studies from this laboratory have shown
this to be particularly important for the survival of SCLC cells in
vivo in that extracellular matrix proteins, such as laminin and
fibronectin found surrounding SCLC metastasis, are able to
protect the cells from chemotherapy-induced apoptosis (Sethi et
al, 1998). Therefore the stimulation of apoptosis as well as inhibi-
tion of SCLC growth would be essential for an inhibition of prolif-
eration of SCLC in vivo.
Neuropeptide antagonism has never been described for antago-
nist G in vivo. To examine this, we chose a rabbit skin model of
inflammation. In this system, bradykinin stimulates oedema
formation via the B2 bradykinin receptor (Williams, 1979;
Armstrong et al, 1995), which is the same subtype involved in
bradykinin-induced Ca2+ mobilization and mitogenesis (Woll and
Rozengurt, 1989; Sethi and Rozengurt, 1991a). However, even
though antagonist G can inhibit functional responses to bradykinin
in vitro, rather than inhibiting oedema, antagonist G directly
induced oedema formation on its own and potentiated oedema
induced by bradykinin. Moreover, the effects of antagonist G on
bradykinin-induced oedema formation were additive suggesting
an independent mechanism of action. This action was not related
to a substance P-like effect, as substance P does not directly induce
oedema in rabbit skin (Brain and Williams, 1985). Since antago-
nist G-induced oedema was not potentiated by the vasodilator
action of PGE2, our results suggest that vasodilatation itself would
not account for the oedema observed with antagonist G. Thus, in
this in vivo model, antagonist G was not behaving as a competitive
neuropeptide receptor antagonist, but rather as an inducer of
oedema formation.
We have shown that antagonist G has little effect on basal
MAPK activity, while producing a sustained and concentration-
dependent increase in JNK activity. Increased JNK activity is often
associated with cellular stresses, such as UV exposure and heat
shock, but also with receptor stimulation via proinflammatory
cytokines and growth factors acting at tyrosine kinase and G-
protein-linked receptors (Coso et al, 1995a; Chen et al, 1996;
Verheij et al, 1996; Butterfield et al, 1997). Although JNK activa-
tion by cellular stress results in cell damage and apoptosis, stimu-
lation of JNK by G-protein-linked receptors often results in
cellular transformation (Prasad, 1995; Heasley et al, 1996). The
finding that antagonist G stimulates JNK activity, despite blocking
other signals via G-protein-linked receptors, provides further
evidence that the sustained activation of JNK occurs by an alterna-
tive mechanism other than neuropeptide receptor antagonism. It
has been suggested that the coordinated activation of the MAPK
and the JNK pathway is important for cell survival, whilst the
sustained activation of JNK in isolation results in cell death (Xia et
al, 1995; Chen et al, 1996). Results from this study would lend
support for this hypothesis, with antagonist G shifting the balance
towards JNK activation and apopotosis. Activation of JNK may
therefore play an important role in inducing apoptosis in SCLC
cells in vivo and may also be important for the proinflammatory
effects of antagonist G seen in rabbit skin.
We show that the activation of JNK and apoptosis by antagonist
G is inhibited by antioxidants and suggest that ROS are involved
in the signalling pathway leading from the receptor/G-protein to
JNK. Previous studies have implicated the heterotrimeric G-
proteins G12 and G13 as being important in the G-protein-linked
receptor activation of JNK in a pathway involving the small
GTPases rac/cdc42 (Coso et al, 1995b; Prasad et al, 1995).
Moreover, in Jurkat T-cells, ROS have been shown to activate JNK
in a pathway involving ras, racl or cdc42 as redox sensors (Lander
et al, 1996), and in cardiac myocytes, hypoxia followed by reoxy-
genation stimulated JNK which was inhibited by n-AC (Laderoute
and Webster, 1997). It has also been demonstrated that activation
of G12/G13 regulates MAPK pathways in a ROS-dependent
fashion, which is regulated by the epidermal growth factor
receptor tyrosine kinase activity (Cunnick et al, 1998; Ghola et al,
1998). G13 has also been shown to play an important role in apop-
tosis as transfection of constitutively activated G13 results in apop-
tosis in two different cell lines (Althoefer et al, 1997). If JNK
activation by antagonist G involves a stimulation of this pathway,
then this may explain the inhibition of antagonist G-induced JNK
activation and induction of apoptosis by ROS.
We have shown that antagonist G directly stimulates G-protein
activity as assessed by increased [35S]-GTPgS binding. These effects
were entirely independent of neuropeptide growth factors. This
property was not shared by suramin, an anti-cancer agent with a
proposed mechanism involving growth factor antagonism and the
selective antagonism of Gs (Freissmuth et al, 1996). These two
antiproliferative agents therefore must have distinct mechanisms of
action. A recent study has demonstrated that a close analogue of
antagonist G, [D-Arg1,D-Phe5,D-Trp7,9,Leu11] substance P (antago-
nist D), increased JNK activity in Swiss 3T3 cells (Jarpe et al, 1998).
The authors proposed the novel terminology ‘biased agonism’,
used to describe ability of the compound to activate some GRP
receptor/G-protein-mediated effects while blocking activation of
others. Our results provide direct evidence for this hypothesis
except that the antagonist G-induced JNK activation was not
dependent on GRP receptors, as not only does antagonist G
interact very weakly with GRP receptors (Woll and Rozengurt,
1990) but the H69 cell line does not express GRP receptors (Kado-
Fong and Malfroy, 1989). Therefore, if the activation of JNK by
antagonist G is receptor-dependent then it must be via a receptor/s
other than the GRP receptor. Antagonist G has the highest potency
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showed that the ability of antagonist G to stimulate [35S]-GTPgS
binding was not blocked by a selective V1A receptor antagonist
suggesting that this effect was not mediated via partial agonism at
the V1A receptor. It is well-established that, as well as having direct
receptor effects, some amphiphylic peptides such as mastoparan
and substance P and its analogues (e.g. antagonist E) are able to
cross or insert into cell membranes and directly promote G-
protein-mediated activation of PLC and other effectors (Mousli et
al, 1990). Therefore, as well as interacting with neuropeptide
receptors, substance P analogues are also able to act directly to
modulate G-protein function. It is conceivable that, owing to its
high lipophilicity (Seckl et al, 1995), antagonist G may have
similar properties to modulate signal transduction directly at the
G-protein level.
We suggest that, as well as inhibiting neuropeptide-mediated
responses, antagonist G also activates some G-protein-mediated
responses. We propose that, in SCLC cells, antagonist G stimulates
G12/13, leading to an activation of JNK, which may account for its
ability to induce apoptosis. We believe that the activation of JNK by
antagonist G may be crucial for its maximal anti-cancer activity, and
may also be responsible for the cardiovascular toxicity seen in vivo.
Whether this effect is mediated by another G-protein-linked receptor
or directly at the G-protein remains to be elucidated. The identifica-
tion of the specific G-proteins involved in antagonist G-modified
signalling in SCLC would be useful for further drug development
and provide additional targets for novel anti-tumour agents. These
findings coupled with the finding that related substance P analogues
can inhibit the growth of tumour lines, e.g. non-SCLC, which are
not dependent on neuropeptide growth factors (Everard et al, 1992),
will have important clinical implications both for the use of antago-
nist G and the future development of anti-proliferative and pro-
apoptotic agents to treat this and other cancers.
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